1. Generics Bulletin
  2. >>Products

Second Tocilizumab Biosimilar Launches In US

Bio-Thera And Biogen’s Tofidence Version Follows Fresenius Kabi’s Tyenne From April

 
• By Dave Wallace

A second tocilizumab biosimilar has been launched in the US, with Bio-Thera and Biogen together introducing their Tofidence version just weeks after Fresenius Kabi launched its first-to-market Tyenne.

Video Game Pixel Art Two Players
Two tocilizumab biosimilars are now fighting it out in the US • Source: chuckchee

Fresenius Kabi’s April launch of its Tyenne (tocilizumab-aazg) rival to Actemra in the US has been swiftly followed by a second biosimilar in the form of Bio-Thera Solutions and Biogen’s Tofidence (tocilizumab-bavi) version.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Discounted Ustekinumab Biosimilars Further Dent J&J’s Q1 Stelara Sales

 
• By Urtė Fultinavičiūtė

With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.